一分钟看懂
这是一项关于Basal Cell Carcinoma的II 期研究，登记的药物或干预包括BO-112，当前状态为研究进行中，已停止招募。登记地点显示中国Beersheba、Haifa、Jerusalem、Rehovot等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BO-112 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Soroka Medical Center · Beersheba
- Rambam Medical Center · Haifa
- Hadassah Ein Kerem Medical Center · Jerusalem
- Kaplan Medical Center · Rehovot
- Hospital Clínic Barcelona · Barcelona
- Hospital de Basurto · Bilbao
- Clínica Universitaria de Navarra (CUN) · Madrid
- Hospital Universitario 12 de Octubre · Madrid
- Complejo Asistencial Universitario de Salamanca · Salamanca
- Instituto Valenciano de Oncología (IVO) · Valencia
公开的入选条件
- 1. Participant must be ≥ 18 years old \[or the legal age of consent in the jurisdiction in which the study is taking place\], at the time of signing the informed consent.
- Type of Participant and Disease Condition
- 2. Has primary resectable low or high risk basal cell carcinoma according to the protocol definition
- 3. Has diagnostic punch biopsy of all lesions intended for injection available prior to the first dose of BO-112.
- 4. Has adequate laboratory values as defined per protocol
- Sex and Contraceptive/Barrier Requirements
- 5. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 24 hours prior to the start of study drug.
- 6. Women of childbearing potential must be willing to use two effective methods of birth control while treated with BO-112 and for 4 weeks after the last treatment. The two forms of birth control authorized are defined as the use of a barrier method of contrac
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06422936；登记信息更新于 2026-09-17。